Following our previous studies on pyridazinone carboxylic acids as potent and selective aldose reductase (ALR2) inhibitors, a new series of benzo[h]cinnolinone carboxylic acids, variously substituted at the positions 4, 7-10 and differently modified both at the central ring and at the acidic side chain, were synthesized and tested as inhibitors of ALR2. Comparison with previously synthesized compounds
Through a cell-based biological screening, the benzocinnolinone derivative (±)-2c was identified as a promising STAT3 inhibitor. Since SAR studies on a series of compounds structurally related to (±)-2c (1c, 2a–p, 3c, 4c, 6) showed that the latter had the most significant inhibitory activity, we investigated in depth its essential structural features. In particular, enantiomeric separation was performed
Behavior of 5,6-dihydrobenzo[<i>h</i>]cinnolinones towards hydrazine. Synthesis of benzo[<i>h</i>]cinnolinones and of 4-Aminobenzo[<i>h</i>]cinnolinones
作者:Stefania Villa、Giacomo Luca Evoli、Giorgio Cignarella、Michela M. Curzu、Gérard A. Pinna
DOI:10.1002/jhet.5570360226
日期:1999.3
Dehydrogenation and amination of 4,4a,5,6-tetrahydro and 5,6-dihydrobenzocinnolinones in refluxing hydrazine hydrate to give new benzo[h]cinnolinones and 4-aminobenzo[h]cinnolinones are reported, and reaction mechanisms proposed. Experiments were also extended to 4,4a-dihydro-5H-indenopyridazinone which underwent hydrazine induced dehydrogenation to 5H-indenopyridazin-3-one but not subsequent amination.
据报道,在回流的水合肼中将4,4a,5,6-四氢和5,6-二氢苯并噻吩甲酮进行脱氢和胺化反应,得到新的苯并[ h ]邻苯二酚和4-氨基苯并[ h ]邻苯二酚,并提出了反应机理。实验还扩展到4,4a-二氢-5 H-茚并哒嗪酮,该肼经历肼诱导的脱氢成5 H-茚并哒嗪-3-酮,但随后没有胺化。
Tricyclic pyridazinone compounds
申请人:Smith Kline & French Laboratories Limited
公开号:US04755511A1
公开(公告)日:1988-07-05
This invention relates to tricyclic pyridazinone compounds, pharmaceutical compositions containing the compounds, and a method of stimulating cardiac activity in a mammal by administering an effective amount of the compound. A compound of the invention is 7-carboxamido-4,4a-dihydro-4a-methyl-[5H]-indeno[1,2-c]-pyridazin-3[2H]-on e.
Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.